Drug intelligence / Profile preview

CDFF0318

Development stage: Phase 1
Lead developer: CTC Bio
Modality: Small Molecules
Administration: Oral

Overview

CDFF0318 is an investigational chemical drug developed by CTC Bio for the treatment of smoking cessation. It has been evaluated in a Phase 1 clinical trial comparing its pharmacokinetics and safety to Champix (varenicline tartrate), indicating it is likely a varenicline-related or generic/formulation product. The drug's mechanism of action is presumed to be similar to varenicline, which acts as a partial agonist at the α4β2 subtype of the neuronal nicotinic acetylcholine receptor, reducing cravings and withdrawal symptoms in nicotine dependence[1][3].

Targets

α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)

Beyond the preview

Go deeper on CDFF0318.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CDFF0318.

Explore the full profile